|
01 Mar 2007 |
Advancis Pharmaceutical Reaches Agreement with FDA for Resubmission of Amoxicillin Pulsys NDA
|
|
01 Mar 2007 |
Organon and Acrux to develop contraceptive sprays
|
|
28 Feb 2007 |
Panacos Begins Phase 1 Clinical Study of Second Generation Maturation Inhibitor PA-040
|
|
28 Feb 2007 |
Roche and Kosan to Initiate Phase 2 Cancer Development Program With Epothilone R1645 (KOS-1584)
|
|
28 Feb 2007 |
Par Pharmaceutical Returns PAR-101 Marketing Rights To Optimer Pharmaceuticals
|
|
28 Feb 2007 |
Clinical Update - DEBIO-9902 SR (ZT-1) Implant For Alzheimer's Disease
|
|
28 Feb 2007 |
MAP Pharmaceuticals Reports Positive Phase 2 Results for its Pediatric Asthma Drug Candidate
|
|
28 Feb 2007 |
PPD Licenses Statin from Ranbaxy Laboratories
|
|
28 Feb 2007 |
TargeGen Announces Successful Completion of Phase I Clinical Trial Of Topical AMD Drug TG100801
|
|
27 Feb 2007 |
Novartis committed to making Galvus(R) available for patients with type 2 diabetes after US regulators issue ''approvable letter''
|
|
27 Feb 2007 |
TorreyPines Therapeutics Initiates Second Phase I Clinical Trial of NGX426, a Potential Novel Oral Treatment for Chronic Pain Conditions
|
|
27 Feb 2007 |
Astellas Receives a Positive CHMP Opinion for EU Marketing Authorisation for FK506 Modified Release as a Once-Daily Immunosuppressant in Organ Transplantation
|
|
27 Feb 2007 |
LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase I Clinical Program
|
|
27 Feb 2007 |
Biofrontera has successfully completed a first human trial with its migraine prophylaxis compound BF-1
|
|
27 Feb 2007 |
Palatin Technologies And King Pharmaceuticals Announce Presentation Regarding Clinical Study Evaluating Bremelanotide In Post-Menopausal Female Sexual Dysfunction Patients
|
|
27 Feb 2007 |
'Encouraging' Major Responses Seen With XYOTAX(TM) in Patients With Taxane-Resistant Androgen Independent Prostate Cancer
|
|
27 Feb 2007 |
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
|
|
27 Feb 2007 |
Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint
|
|
27 Feb 2007 |
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
|
|
27 Feb 2007 |
GSK initiates first global Phase III study of Tykerb® (lapatinib) in head and neck cancer
|
|
27 Feb 2007 |
Othera Pharmaceuticals Presents New AMD Data at Angiogenesis 2007 Symposium
|
|
27 Feb 2007 |
Senetek PLC Announces Clinical Update on Invicorp(R)
|
|
27 Feb 2007 |
Trius Therapeutics Enters into License Agreement with Dong-A Pharmaceuticals for Novel Anti-bacterial Agent
|
|
24 Feb 2007 |
Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine dimesylate) as a Novel Treatment for ADHD
|
|
24 Feb 2007 |
Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
|
